Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma
| Autor: | Emiddio, Barletta, Francesco, Fiore, Bruno, Daniele, Alessandro, Ottaiano, Roberto, D'Angelo, Ettore, Ferrari, Roberta, Formato, Anna, Tortoriello, Giacinto, Turitto, Giovanni Salvatore, Bruni, Sandro, Pignata, Rosario Vincenzo, Iaffaioli |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male Time Factors Body Weight Leucovorin Antineoplastic Agents Adenocarcinoma Middle Aged Carboplatin Pancreatic Neoplasms Treatment Outcome Antineoplastic Combined Chemotherapy Protocols Disease Progression Humans Infusions Intra-Arterial Female Fluorouracil Neoplasm Metastasis Aged Epirubicin Retrospective Studies |
| Zdroj: | Frontiers in bioscience : a journal and virtual library. 11 |
| ISSN: | 1093-9946 |
| Popis: | The present study was conducted to evaluate activity and toxicity of the FLEC (folinic acid 100 mg/m2; 5-fluorouracil 1000 mg/m2; carboplatin 300 mg/m2; epirubicin 60 mg/m2) schedule as second-line treatment for progressive locally advanced or metastatic pancreatic cancer (LAMPC). FLEC was administered every 3 weeks with an angiographic catheter introduced into the tumor vascular bed. Thirty-two patients were enrolled. Twenty patients had a PS of 2. Twenty-five patients had metastatic disease to liver. Seven (21.9%) partial responses were observed (WHO criteria). Fifteen patients (46.9%) had stable disease and ten patients (31.2%) had progressive disease. The median OS from the diagnosis was 11.8 months. PS (p=0.0308) and pain (WHO scale, p=0.0222; analogic scale, p=0.0446) significantly improved after therapy. No patient discontinued treatment because of toxicity (NCI-CTC criteria). The current study shows that intraarterial chemotherapy is a good therapeutic option in second-line treatment of LAMPC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|